Bandar Alqarni/X
Sep 29, 2025, 11:36
Bandar Alqarni: Smoflipid 20% Use in IVF Protocols
Bandar Alqarni, Pharmacist in Riyadh, shared a post on X:
“Smoflipid 20% is gaining attention for its off-label use in IVF protocols, especially in cases of Recurrent Implantation Failure (RIF) or Recurrent Pregnancy Loss (RPL).
It may help by:
- Reducing NK cell activity
- Enhancing immune tolerance
- Supporting embryo implantation
While not considered a formal treatment, it is an option in select cases after ruling out organic and chromosomal causes. Its use is under strict medical supervision, often as part of an integrated immunotherapy plan.
Always consult your fertility specialist.”
-
Oct 11, 2025, 06:44The Global IVF Market Is Set to Reach $65B by 2032 – Meddilink
-
Dec 21, 2025, 02:55Epigenetic Links Between Paternal Age, Reproduction and Offspring Health – Reproduction and Fertility
-
Dec 21, 2025, 02:43Medicines and Pregnancy: ANSM Proposes New Labeling – B’RIGHT
-
Dec 21, 2025, 02:28Steven Palter: It is time to retire the out of date ‘2 week wait’ for pregnancy tests after IVF
-
Dec 21, 2025, 02:24Thorsten Waloschek: New Study Highlights Preeclampsia Risk Stratification Benefits
-
Dec 21, 2025, 02:15Siddhartha Yadav: New ASCO Guideline for Managing Cancer During Pregnancy
-
Dec 21, 2025, 01:56New Patient Resource on Thyroid Issues in Pregnancy – RCOG
-
Dec 21, 2025, 01:49CDC Releases 2024 Pregnancy Mortality Data – Preeclampsia Foundation
-
Dec 21, 2025, 01:30Caitlin Wyrwoll: New Insights on Maternal Health and Extreme Heat
-
Dec 20, 2025, 10:57Clare Pin-Chia Huang: New Research Links Maternal Diabetes to Pregnancy Risks